Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0581-0001 in healthy adults and hepatic steatosis
NCT05599945Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0581-0001 in hepatic steatosis (7 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at 52 weeks. Started Nov 2022; status: completed.
02
Drugs
NNC0581-0001
03
Conditions
hepatic steatosis
Beyond the preview
Go deeper on NCT05599945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599945.